HK1133601A1 - Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides - Google Patents

Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides

Info

Publication number
HK1133601A1
HK1133601A1 HK10101587.5A HK10101587A HK1133601A1 HK 1133601 A1 HK1133601 A1 HK 1133601A1 HK 10101587 A HK10101587 A HK 10101587A HK 1133601 A1 HK1133601 A1 HK 1133601A1
Authority
HK
Hong Kong
Prior art keywords
peptides
growth factor
vascular endothelial
factor receptor
endothelial growth
Prior art date
Application number
HK10101587.5A
Other languages
English (en)
Inventor
Hideaki Tahara
Takuya Tsunoda
Masabumi Shibuya
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of HK1133601A1 publication Critical patent/HK1133601A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
HK10101587.5A 2005-02-28 2008-05-06 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides HK1133601A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65752705P 2005-02-28 2005-02-28
HK08105026.9A HK1110529A1 (en) 2005-02-28 2008-05-06 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides

Publications (1)

Publication Number Publication Date
HK1133601A1 true HK1133601A1 (en) 2010-04-01

Family

ID=36581423

Family Applications (3)

Application Number Title Priority Date Filing Date
HK10101587.5A HK1133601A1 (en) 2005-02-28 2008-05-06 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
HK08105026.9A HK1110529A1 (en) 2005-02-28 2008-05-06 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
HK11106949.6A HK1152873A1 (en) 2005-02-28 2008-05-06 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK08105026.9A HK1110529A1 (en) 2005-02-28 2008-05-06 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
HK11106949.6A HK1152873A1 (en) 2005-02-28 2008-05-06 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides

Country Status (11)

Country Link
US (4) US7919099B2 (de)
EP (4) EP2289532A1 (de)
JP (3) JP4931154B2 (de)
CY (1) CY1112867T1 (de)
DK (3) DK2289533T3 (de)
ES (3) ES2385396T3 (de)
HK (3) HK1133601A1 (de)
PL (3) PL2095822T3 (de)
PT (3) PT2289533E (de)
SI (3) SI1855707T1 (de)
WO (1) WO2006093030A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1548032T3 (da) * 2002-09-12 2009-08-17 Oncotherapy Science Inc KDR-peptider og vacciner indeholdende disse
US20100297157A1 (en) * 2007-02-16 2010-11-25 Yasuhiro Tamaki Vaccine therapy for choroidal neovascularization
TW201109029A (en) * 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
US20200147194A1 (en) * 2017-05-19 2020-05-14 Keio University Peptide vaccine and peptide vaccine composition for cranial nerve disease
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH0418667A (ja) * 1989-07-05 1992-01-22 Tohoku Nippon Denki Software Kk 自動配送システム
JPH0350140A (ja) * 1989-07-18 1991-03-04 Seiko Epson Corp 分布屈折率レンズの製造方法
PT694042E (pt) * 1993-03-25 2005-02-28 Merck & Co Inc Inibidor do factor de crescimento de celulas endoteliais vasculares
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6200954B1 (en) * 1998-09-04 2001-03-13 National University Of Singapore Small peptides having potent anti-angiogenic activity
AU2002257647A1 (en) * 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
FI110549B (fi) 2001-06-29 2003-02-14 Nokia Corp Menetelmä ja järjestely liikkeen määrittämiseksi
US20030157101A1 (en) * 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
CA2469274A1 (en) 2001-12-10 2003-06-19 Kyogo Itoh Tumor antigens
CU23178A1 (es) 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
JP2004018667A (ja) 2002-06-17 2004-01-22 National Institute Of Advanced Industrial & Technology 高分子化合物膜の表面における炭酸カルシウム被膜の製造方法
JP4406607B2 (ja) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
DK1548032T3 (da) 2002-09-12 2009-08-17 Oncotherapy Science Inc KDR-peptider og vacciner indeholdende disse
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization

Also Published As

Publication number Publication date
PL2095822T3 (pl) 2014-03-31
US7919099B2 (en) 2011-04-05
HK1110529A1 (en) 2008-07-18
JP4843095B2 (ja) 2011-12-21
ES2435650T3 (es) 2013-12-20
PT1855707E (pt) 2012-05-25
DK1855707T3 (da) 2012-07-16
US20110250219A1 (en) 2011-10-13
PT2095822E (pt) 2013-12-09
SI2095822T1 (sl) 2013-12-31
US8663647B2 (en) 2014-03-04
US20090214581A1 (en) 2009-08-27
ES2385396T3 (es) 2012-07-24
US8257711B2 (en) 2012-09-04
EP1855707B1 (de) 2012-04-04
JP4931154B2 (ja) 2012-05-16
EP2289532A1 (de) 2011-03-02
EP2095822B1 (de) 2013-10-16
EP2289533B1 (de) 2013-09-18
SI2289533T1 (sl) 2013-11-29
CY1112867T1 (el) 2016-04-13
PL2289533T3 (pl) 2014-02-28
EP2095822A1 (de) 2009-09-02
US20140186381A1 (en) 2014-07-03
EP2289533A1 (de) 2011-03-02
JP5789820B2 (ja) 2015-10-07
WO2006093030A1 (en) 2006-09-08
JP2008531463A (ja) 2008-08-14
DK2289533T3 (da) 2013-12-02
PT2289533E (pt) 2013-12-10
DK2095822T3 (da) 2014-01-13
PL1855707T3 (pl) 2012-08-31
HK1152873A1 (en) 2012-03-16
JP2012102105A (ja) 2012-05-31
JP2010265269A (ja) 2010-11-25
ES2442294T3 (es) 2014-02-11
SI1855707T1 (sl) 2012-07-31
EP1855707A1 (de) 2007-11-21
US20120294877A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
HK1133601A1 (en) Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
HK1167325A1 (en) Antibodies against vascular endothelial growth factor receptor-1 -1
EP1699484A4 (de) Humanisierte antikörper gegen vaskulären endothelialen wachstumsfaktor
IL230645A (en) Antibodies against activin a or b and their use to promote bone growth
IL186959A0 (en) Peptides and pharmaceutical compositions containing the same
EP2326718A4 (de) Inhbb-epitop-peptide und diese enthaltende impfstoffe
PL2272873T3 (pl) Przeciwciała przeciw receptorowi insulinopodobnego czynnika wzrostu I i ich zastosowania
HK1173929A1 (en) A support for supporting the neck and head of a human being
EP1784142A4 (de) Muskel-skelett-implantat mit bioaktivem gefälle
IL182267A0 (en) Novel anthranilamide pyridinureas as vascular endothelial growth factor
PL1838341T3 (pl) Kompozycja szczepionki obejmująca białko wiążące fibronektynę lub peptyd wiążący fibronektynę
EP1948676A4 (de) Biologisch wirksames substanz-protein-konjugat und stabilisierung einer biologisch aktiven substanz damit
IL186376A0 (en) Bone cement compositions and the like comprising an rnaiii-inhibiting peptide
EP1969483A4 (de) Änderung des inhalts physischer post
ZA200302872B (en) Graded Crystallization of container finishes.
HK1157397A1 (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same rab6kifl/kif20a
PL375807A1 (pl) Podpora myśliwska
ZA200801874B (en) Antigenic peptides and their use
ZA200701496B (en) Post-foaming dental mousse and methods utilizing the same
EP2108698A4 (de) Vaskuläres endothelzell-bindendes peptid
GB2417482B (en) Box or container support
ZA200800566B (en) Therapeutic peptides and vaccines
GB0508726D0 (en) Polypeptide, vaccine and use thereof
GB2425450B (en) Plant and container support
GB0418390D0 (en) Pot handler & cane support

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170217